Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating

Stock Track05-01

Pacira Pharmaceuticals' stock surged 5.10% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.

The significant pre-market gain follows the company's release of first-quarter results that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the FactSet consensus estimate of $0.55, while revenue rose to $177.4 million from $168.9 million a year earlier and surpassed the $171.8 million analyst forecast. The company also maintained its full-year 2026 revenue guidance of $745 million to $770 million.

Adding to the positive sentiment, analyst firm Needham maintained its Buy rating on Pacira BioSciences, providing further confidence in the company's outlook to market participants.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1117557866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-01 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117557866","market":"nz","top_or_hot":-1,"title":"Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating","media":"Stock Track","content":"<p>Pacira Pharmaceuticals' stock surged 5.10% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.</p><p>The significant pre-market gain follows the company's release of first-quarter results that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the FactSet consensus estimate of $0.55, while revenue rose to $177.4 million from $168.9 million a year earlier and surpassed the $171.8 million analyst forecast. The company also maintained its full-year 2026 revenue guidance of $745 million to $770 million.</p><p>Adding to the positive sentiment, analyst firm Needham maintained its Buy rating on Pacira BioSciences, providing further confidence in the company's outlook to market participants.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Pacira Pharmaceuticals Soars 5.10% in Pre-Market on Strong Q1 Results and Maintained Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-01 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pacira Pharmaceuticals' stock surged 5.10% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.</p><p>The significant pre-market gain follows the company's release of first-quarter results that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the FactSet consensus estimate of $0.55, while revenue rose to $177.4 million from $168.9 million a year earlier and surpassed the $171.8 million analyst forecast. The company also maintained its full-year 2026 revenue guidance of $745 million to $770 million.</p><p>Adding to the positive sentiment, analyst firm Needham maintained its Buy rating on Pacira BioSciences, providing further confidence in the company's outlook to market participants.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PCRX","symbol_name":"Pacira Pharmaceuticals","start_time":0,"source_url":"","article_id":"1117557866","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117557866","pubTimestamp":1777642238,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Pacira Pharmaceuticals' stock surged 5.10% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.The significant pre-market gain follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PCRX":"Pacira Pharmaceuticals"},"translate_title":"个股追踪|Pacira制药盘前大涨5.10%Q1业绩强劲维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1},"content_text":"Pacira Pharmaceuticals' stock surged 5.10% during pre-market trading on Friday, indicating strong investor interest ahead of the regular session.The significant pre-market gain follows the company's release of first-quarter results that exceeded analyst expectations. Pacira reported Q1 non-GAAP earnings of $0.60 per diluted share, beating the FactSet consensus estimate of $0.55, while revenue rose to $177.4 million from $168.9 million a year earlier and surpassed the $171.8 million analyst forecast. The company also maintained its full-year 2026 revenue guidance of $745 million to $770 million.Adding to the positive sentiment, analyst firm Needham maintained its Buy rating on Pacira BioSciences, providing further confidence in the company's outlook to market participants.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117557866","isCrawlerRequest":true}